Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 4—April 2006
Research

Contrasting Pediatric and Adult Methicillin-resistant Staphylococcus aureus Isolates

Michael Z. David*Comments to Author , Susan E. Crawford*, Susan Boyle-Vavra*, Mark A. Hostetler*, Daniel C. Kim*, and Robert S. Daum*
Author affiliations: *University of Chicago, Chicago, Illinois, USA

Main Article

Table 3

Percentage of methicillin-resistant Staphylococcus aureus (MRSA) resistant to non–β-lactam antimicrobial drugs among pediatric and adult patients, stratified by hospital- and by community-associated designation

In addition to methicillin,* % resistant to Adult community-associated, % (n = 280) Pediatric community-associated, % (n = 177) p value† Adult hospital-associated, % (n = 97) Pediatric hospital-associated, % (n = 24) p value‡
No other antimicrobial drugs§ 3.6 9.6 0.001 3.1 4.2 0.99
Ciprofloxacin 62.1 10.7 <0.001 87.6 62.5 0.004
Clindamycin
Resistant¶ 51.8 7.3 <0.001 74.2 75.0 0.94
D-test positive# 20.5 15.2 0.29 50 0 0.48
Erythromycin 93.2 87.0 0.03 93.8 95.8 0.99
Gentamicin 11.1 1.1 <0.001 14.4 37.5 0.01
Rifampin 1.8 0 0.16 1.0 0 0.99
Tetracycline** 19.9 6.4 <0.001 13.5 8.3 0.73
TMP-SMX†† 0 0 NA 0 0 NA
Vancomycin 0 0 NA 0 0 NA
>3 non–β-lactam antimicrobial drugs 52.3 6.4 <0.001 76.0 66.7 0.35

*Methicillin resistance inferred from oxacillin resistance test.
†p value compares community-associated (CA) adult and pediatric isolates for resistance to each antimicrobial drug or test, χ2 or Fisher exact test. NA, not applicable.
‡p value compares hospital-associated (HA) MRSA adult and pediatric isolates for resistance to each antimicrobial drug or test, χ2 or Fisher exact test.
§Includes erythromycin, clindamycin, ciprofloxacin, gentamicin, rifampin, and tetracycline and does not include D-test–positive results.
¶Data in this row represent single-agent Vitek testing results for clindamycin.
#112 (97%) of the adult CA-MRSA isolates, 125 (89%) of the pediatric CA-MRSA isolates, 18 (95%) of the adult HA-MRSA isolates, and 2 (67%) of the pediatric HA-MRSA isolates that were erythromycin resistant and clindamycin susceptible by Vitek were evaluated by D-testing.
**Nine isolates not tested for susceptibility to tetracycline were omitted.
††TMP-SMX, trimethoprim-sulfamethoxazole. Only 100 adult CA-MRSA, 121 pediatric CA-MRSA, 15 adult HA-MRSA, and 2 pediatric HA-MRSA isolates that were clindamycin susceptible and erythromycin resistant were tested for TMP-SMX susceptibility.

Main Article

Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external